What Key Growth Drivers Are Shaping The Renal Cell Carcinoma Market Forecast Toward $5.84 Billion?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Much Will The Renal Cell Carcinoma Market Be Worth By 2029?
In recent times, there has been a consistent growth in the renal cell carcinoma market size. The market, which presently stands at $4.81 billion in 2024, will escalate to $4.96 billion in 2025, with a compound annual growth rate (CAGR) of 3.0%. Several factors have contributed to this growth during the specified period, including an increased occurrence of kidney cancer, a surge in the aging population, growing acceptance of targeted therapies, an increase in cancer screening awareness, enhancements in healthcare infrastructure, as well as a rise in investment towards oncology research and development.
Expectations are set for the renal cell carcinoma market size to experience consistent growth over the coming years, amounting to $5.84 billion in 2029, with a compound annual growth rate (CAGR) of 4.2%. The predicted growth within this forecast period can be linked to the rise in personalized medicine usage, increasing cognizance of early cancer detection, heightened oncology healthcare investment, bettered healthcare accessibility, and the expansion of clinical trials and research into new therapies. Anchored trends for the forecast period encompass the application of AI to achieve precision diagnostics, creation of targeted therapies, advancements in immunotherapy, progress in identifying biomarkers, adoption of less invasive surgical approaches, and improvements in imaging technologies.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20944&type=smp
What Market Forces Are Contributing To The Growth Of The Renal Cell Carcinoma Market?
The anticipated increase in the ageing population is likely to stimulate the growth of the renal cell carcinoma market. This aged demographic, typically 65 years and older, often has specific needs in terms of health care and social services. The expansion in the elderly population can be attributed to advancements in medical care, improved nutrition, and extended life durations. Renal cell carcinoma (RCC) is becoming more common in the elderly population, underlining the necessity for age-specific screening and treatment schemes. For example, the Population Reference Bureau, a US-based non-profit organization dedicated to statistical research, published a report in January 2024, predicting that the number of Americans aged 65 and older is expected to increase from 58 million in 2022 to 82 million by 2050, signifying a 47% increase. Consequently, the increase in the elderly population is propelling the growth of the renal cell carcinoma market.
Which Segments Define The Structure Of The Renal Cell Carcinoma Market?
The renal cell carcinomamarket covered in this report is segmented –
1) By Type: Clear Cell Renal Cell Carcinoma (RCC); Papillary Renal Cell Carcinoma (RCC); Chromophobe Renal Cell Carcinoma (RCC)
2) By Diagnosis: Urine Tests; Computed Tomography (CT) Scan; Nephrectomy; Blood Tests; Ultrasound; Biopsy
3) By Treatment: Medication; Ablation; Targeted Therapy; Chemotherapy; Surgery; Other Treatments
4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
Subsegments:
1) By Clear Cell Renal Cell Carcinoma (RCC): Sporadic Clear Cell RCC; Hereditary Clear Cell RCC
2) By Papillary Renal Cell Carcinoma (RCC): Type 1 Papillary RCC; Type 2 Papillary RCC
3) By Chromophobe Renal Cell Carcinoma (RCC): Classic Chromophobe RCC; Hybrid Chromophobe RCC
Which Long-Term Trends Will Play A Crucial Role In The Renal Cell Carcinoma Market?
Prominent organizations in the renal cell carcinoma sector are prioritizing the innovation of products equipped with cutting-edge technology. They are particularly interested in harnessing artificial intelligence (AI) to optimise the evaluation process of kidney biopsies which in turn aids in diagnosis precision, procedural streamlining and enhanced patient outcomes. An AI-enhanced solution for kidney biopsy analysis is a technological tool that utilises machine learning algorithms and computer vision with the intent to support pathologists and nephrologists in assessing kidney tissue samples. The objective of these solutions is to boost diagnostic accuracy, streamline efficiency and ensure consistent evaluations of kidney health. For example, in March 2024, NephroPath platform was launched by Aiosyn, a software enterprise based in the Netherlands, with the goal to utilize AI for evaluating kidney biopsies. Its platform employs computational pathology algorithms to thoroughly examine histological biomarkers in kidney biopsies, including categorizing tissue types, marking interstitial fibrosis, and gauging and assessing glomeruli in a precise manner. This AI-influenced evaluation ensures consistent, comprehensive, and highly repeatable scoring of renal pathology biomarkers, circumventing the limitations of traditional scoring techniques and observer’s subjectivity.
Which Firms Are Making The Biggest Impact In The Renal Cell Carcinoma Market?
Major companies operating in the renal cell carcinoma market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Bristol Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories, Novartis AG, Fresenius Kabi AG, GSK plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Viatris Inc. (Mylan N.V.), Astellas Pharma Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Cipla Inc., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Exelixis Inc., Nektar Therapeutics
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/renal-cell-carcinoma-global-market-report
Which Region Is Forecasted To Lead The Renal Cell Carcinoma Market In The Coming Years?
North America was the largest region in the renal cell carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renal cell carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=20944&type=smp
Browse Through More Reports Similar to the Global Renal Cell Carcinoma Market 2025, By The Business Research Company
Renal Biomarkers Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report
End Stage Renal Disease Esrd Drug Global Market Report 2025
Hepatorenal Syndrome Treatment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
